IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity

• Published in: Current controlled trials in cardiovascular medicine Vol. 23; no. 1; pp. 739 - 26
• Main Authors: Leone, Caterina, Di Stefano, Giulia, Di Pietro, Giuseppe, Bloms-Funke, Petra, Boesl, Irmgard, Caspani, Ombretta, Chapman, Sonya C., Finnerup, Nanna Brix, Garcia-Larrea, Luis, Li, Tom, Goetz, Marcus, Mouraux, André, Pelz, Bernhard, Pogatzki-Zahn, Esther, Schilder, Andreas, Schnetter, Erik, Schubart, Karin, Tracey, Irene, Troconiz, Inaki F., Van Niel, Hans, Hernandez, Jose Miguel Vela, Vincent, Katy, Vollert, Jan, Wanigasekera, Vishvarani, Wittayer, Matthias, Phillips, Keith G., Truini, Andrea, Treede, Rolf-Detlef
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 05.09.2022; BioMed Central; BMC
• Subjects: Analgesics; Biological markers; Biomarkers; Brain research; Brain stem; Care and treatment; Chronic pain; Double-blind studies; Drug dosages; Health aspects; Hyperalgesia; Innovations; Lacosamide; Neurosciences; Pain; Pharmaceuticals; Pharmacodynamics; Pharmacokinetics; Physiological aspects; PK/PD; Pregabalin; RIII flexion reflex; Spinal cord; Study Protocol; Testing; Germany; United Kingdom > UK; Aachen Germany; Rome Italy; Denmark; Italy; Aarhus Denmark; Spain

Background IMI2-PainCare-BioPain-RCT2 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug effects on specific compartments of the nociceptive system that could serve to accelerate the future development of analgesics. IMI2-PainCare-BioPain-RC...